Problem statement

Cardiovascular diseases have rapidly become a major cause of premature death and disability in many low and middle-income countries (LMIC), including Iran. The SUPPORT-CVD trial has been specifically designed to address the unmet need for a rigorously developed and adequately powered study to achieve an affordable, integrated and sustainable solution for the long-term management of disadvantaged populations with –or- at risk of common and major cardiovascular diseases.

Objective

The overall aim of this RCT is to investigate the effectiveness and cost-effectiveness of an innovative, low-cost and community-based healthcare intervention in reducing the risk of serious cardiovascular events (fatal or non-fatal stroke, or non-fatal myocardial infarction or coronary death) among high-risk individuals in disadvantaged communities.

Executive Summary

In this study, we will implement the intervention (a polypill containing blood pressure lowering, anti-platelet and cholesterol lowering drugs) in a two-armed large-scale cluster randomised trial of 306 rural health centres (about 450 community health workers, 55,000 patients with complete CVD screening and 30,000 high-risk individuals) and measure its impact on serious cardiovascular events in the high-risk group over the 5-year study period versus the current care in the control arm.

Contact Info

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences

No. 10, Al-e-Ahmad and Chamran Highway intersection, Tehran

Postcode: 1411713136

+9821-88631293

This email address is being protected from spambots. You need JavaScript enabled to view it.